Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Rev. chil. enferm. respir ; Rev. chil. enferm. respir;31(2): 105-108, jun. 2015. ilus
Artigo em Espanhol | LILACS | ID: lil-757185

RESUMO

In Chile, hydrochlorothiazide is frequently prescribed as first line antihypertensive therapy. Among it’s well known adverse reactions are: electrolytic disorders, hyperuricemia, dyslipidemia, agranulocytosis and azotemia. Acute pulmonary edema is a rare and potentially lethal adverse effect. Only 50 cases have been reported since 1968. In this article, we discuss a case of a 70 year old woman who, one hour after the ingestion of hydrochlorotiazide, presented acute and progressive dyspnea. Her clinical and radiologic findings are compatible with non-cardiogenic acute pulmonary edema.


En Chile, la hidroclorotiazida se utiliza ampliamente como terapia de primera línea en la hipertensión arterial esencial. Entre los efectos adversos más conocidos destacan: trastornos hidroelectrolíticos, hiperuricemia, dislipidemia, azotemia, entre otros. El edema pulmonar agudo es un efecto adverso infrecuente y potencialmente grave. Desde 1968, se han reportado 50 casos clínicos en la literatura. En este artículo presentamos el caso clínico de una mujer de 70 años atendida en el Hospital Santiago Oriente quien, una hora posterior a la ingesta de hidroclorotiazida, presenta disnea aguda progresiva. El estudio clínico y radiológico es compatible con edema pulmonar agudo no cardiogénico.


Assuntos
Humanos , Feminino , Idoso , Edema Pulmonar/induzido quimicamente , Diuréticos/efeitos adversos , Hidroclorotiazida/efeitos adversos , Edema Pulmonar/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos , Doença Aguda , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Unidades de Terapia Intensiva
2.
Cir Cir ; 72(4): 323-6, 2004.
Artigo em Espanhol | MEDLINE | ID: mdl-15469753

RESUMO

Mediastinum hemangioma is a rare benign tumor. We performed surgery and present the first reported case in Chile. The patient is a 24-year-old symptomatic woman, referred to our hospital from a rural health center. The patient had all routine preoperative studies, chest radiographs and computed tomography of the thorax. We performed a median sternotomy with a complete resection of the mass. During the 36-month follow-up, she was well, asymptomatic and without relapse evidence. A review of the most outstanding characteristics of this rare tumor is presented.


Assuntos
Hemangioma Cavernoso/complicações , Neoplasias do Mediastino/complicações , Trombose/complicações , Adulto , Feminino , Hemangioma Cavernoso/diagnóstico , Hemangioma Cavernoso/cirurgia , Humanos , Neoplasias do Mediastino/diagnóstico , Neoplasias do Mediastino/cirurgia , Trombose/diagnóstico , Trombose/cirurgia
3.
Rev. méd. Chile ; 130(7): 798-802, jul. 2002. tab, graf
Artigo em Espanhol | LILACS | ID: lil-323256

RESUMO

We report a 58 years old male that developed a bone marrow aplasia associated to the use of ticlopidine, prescribed after coronary artery stenting. The patient developed a pneumonia as a complication. He was admitted to the Intermediate Treatment Unit, receiving wide spectrum antimicrobial therapy and a granulocyte colony stimulating factor (Neupogen(r)) with favourable response. Ticlodipine is an effective anti-platelet agent, but has serious hematological and other side effects. Its prescription requires a close follow up and search for complications


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Ticlopidina , Doenças da Medula Óssea/induzido quimicamente , Pancitopenia , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Doença das Coronárias
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA